ArticleThe oncologist2026
Predictive modeling of treatment-related thyroid dysfunction and prognostic implication in advanced nasopharyngeal carcinoma with PD-1 inhibitors.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTreatment-related thyroid dysfunction (trTD) frequently occurs in advanced nasopharyngeal carcinoma (NPC) patients treated with PD-1 inhibitors. Its clinical features, incidence, and prognostic value remain unclear. This study aimed to characterize trTD and assess its impact on survival.
methodsWe retrospectively analyzed 168 advanced NPC patients who received PD-1 inhibitor therapy between 2019 and 2022. Cox proportional hazards models and Kaplan-Meier analysis were used to assess the prognostic significance of trTD. Clinical factors associated with trTD were identified through logistic regression. A predictive nomogram was constructed and evaluated using receiver operating characteristic (ROC) and calibration curves. Spearman correlation analysis was performed to assess the dynamic relationship between thyroid function indicators and treatment duration.
resultsTrTD developed in 49.4% of patients, mostly mild, including hyperthyroidism, hypothyroidism, and biphasic dysfunction. TrTD was independently associated with improved progression free survival (PFS). Female, elevated ALB, ALT, and TBIL were independent risk factors for trTD. The nomogram constructed by combining these factors and thyroid indicators had good prediction accuracy (AUC = 0.781). Dynamic analysis revealed that TSH levels significantly increased after the fourth treatment cycle, preceding changes in FT3 and FT4, suggesting TSH as a potential early biomarker for trTD onset.
conclusionThis study identifies trTD as a common event associated with improved survival in advanced NPC patients treated with PD-1 inhibitors. A predictive nomogram and early TSH elevation provide valuable tools for risk stratification and personalized immunotherapy monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.